TY - JOUR AU - Reid, B. M. AU - Permuth, J. B. AU - Sellers, T. A. PY - 2017 DA - 2017// TI - Epidemiology of ovarian cancer: a review.Cancer biology and JO - Medicine VL - 14 ID - Reid2017 ER - TY - STD TI - Piao J, Lee EJ, Lee M. Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. Gynecol Oncol. 2020;157:542-8. ID - ref2 ER - TY - JOUR AU - Bookman, M. A. AU - Okamoto, A. AU - Stuart, G. AU - Yanaihara, N. AU - Aoki, D. AU - Bacon, M. PY - 2017 DA - 2017// TI - Harmonising clinical trials within the gynecologic cancer intergroup: consensus and unmet needs from the fifth ovarian cancer consensus conference JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx449 DO - 10.1093/annonc/mdx449 ID - Bookman2017 ER - TY - JOUR AU - McGee, J. AU - Bookman, M. AU - Harter, P. AU - Marth, C. AU - McNeish, I. AU - Moore, K. N. PY - 2017 DA - 2017// TI - Fifth ovarian cancer consensus conference: Individualized therapy and patient factors JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx010 DO - 10.1093/annonc/mdx010 ID - McGee2017 ER - TY - JOUR AU - Landrum, L. M. AU - Brady, W. E. AU - Armstrong, D. K. AU - Moore, K. N. AU - DiSilvestro, P. A. AU - O'Malley, D. M. PY - 2016 DA - 2016// TI - A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG oncology/gynecologic oncology group study JO - Gynecol Oncol VL - 140 UR - https://doi.org/10.1016/j.ygyno.2015.11.024 DO - 10.1016/j.ygyno.2015.11.024 ID - Landrum2016 ER - TY - JOUR AU - Buechel, M. AU - Herzog, T. J. AU - Westin, S. N. AU - Coleman, R. L. AU - Monk, B. J. AU - Moore, K. N. PY - 2019 DA - 2019// TI - Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz104 DO - 10.1093/annonc/mdz104 ID - Buechel2019 ER - TY - JOUR AU - Corrado, G. AU - Salutari, V. AU - Palluzzi, E. AU - Distefano, M. G. AU - Scambia, G. AU - Ferrandina, G. PY - 2017 DA - 2017// TI - Optimizing treatment in recurrent epithelial ovarian cancer JO - Expert Rev Anticancer Ther VL - 17 UR - https://doi.org/10.1080/14737140.2017.1398088 DO - 10.1080/14737140.2017.1398088 ID - Corrado2017 ER - TY - JOUR AU - Madrid Paredes, A. AU - Vallejo, I. AU - Carrasco, M. AU - Valencia, C. AU - Artime, F. AU - Calleja, M. PY - 2015 DA - 2015// TI - Prescription profile and impact after the pegylated liposomal doxorubicin shortage alert JO - Eur J Hosp Pharm VL - 22 ID - Madrid Paredes2015 ER - TY - JOUR AU - Cannon, T. L. AU - Lai, D. W. AU - Hirsch, D. AU - Delacure, M. AU - Downey, A. AU - Kerr, A. R. PY - 2012 DA - 2012// TI - Squamous cell carcinoma of the oral cavity in nonsmoking women: A new and unusual complication of chemotherapy for recurrent ovarian cancer? JO - Oncologist VL - 17 UR - https://doi.org/10.1634/theoncologist.2011-0216 DO - 10.1634/theoncologist.2011-0216 ID - Cannon2012 ER - TY - JOUR AU - Gibson, J. M. AU - Alzghari, S. AU - Ahn, C. AU - Trantham, H. AU - La-Beck, N. M. PY - 2013 DA - 2013// TI - The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials JO - Oncologist VL - 18 UR - https://doi.org/10.1634/theoncologist.2013-0126 DO - 10.1634/theoncologist.2013-0126 ID - Gibson2013 ER - TY - JOUR AU - Lawrie, T. A. AU - Bryant, A. AU - Cameron, A. AU - Gray, E. AU - Morrison, J. PY - 2013 DA - 2013// TI - Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer JO - Cochrane Database Syst Rev VL - 7 ID - Lawrie2013 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Wagner, U. AU - Aavall-Lundqvist, E. AU - Gebski, V. AU - Heywood, M. AU - Vasey, P. A. PY - 2010 DA - 2010// TI - Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.7519 DO - 10.1200/JCO.2009.25.7519 ID - Pujade-Lauraine2010 ER - TY - JOUR AU - Gladieff, L. AU - Ferrero, A. AU - Rauglaudre, G. AU - Brown, C. AU - Vasey, P. AU - Reinthaller, A. PY - 2012 DA - 2012// TI - Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr441 DO - 10.1093/annonc/mdr441 ID - Gladieff2012 ER - TY - JOUR AU - Mahner, S. AU - Meier, W. AU - Bois, A. AU - Brown, C. AU - Lorusso, D. AU - Dell'Anna, T. PY - 2015 DA - 2015// TI - Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2014.11.017 DO - 10.1016/j.ejca.2014.11.017 ID - Mahner2015 ER - TY - STD TI - Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med. 2010;8:3. ID - ref15 ER - TY - JOUR AU - Mutch, D. G. AU - Orlando, M. AU - Goss, T. AU - Teneriello, M. G. AU - Gordon, A. N. AU - McMeekin, S. D. PY - 2007 DA - 2007// TI - Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.6735 DO - 10.1200/JCO.2006.09.6735 ID - Mutch2007 ER - TY - JOUR AU - Ferrandina, G. AU - Ludovisi, M. AU - Lorusso, D. AU - Pignata, S. AU - Breda, E. AU - Savarese, A. PY - 2008 DA - 2008// TI - Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.6606 DO - 10.1200/JCO.2007.13.6606 ID - Ferrandina2008 ER - TY - JOUR AU - Vergote, I. AU - Finkler, N. J. AU - Hall, J. B. AU - Melnyk, O. AU - Edwards, R. P. AU - Jones, M. PY - 2010 DA - 2010// TI - Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer JO - Int J Gynecol Cancer VL - 20 UR - https://doi.org/10.1111/IGC.0b013e3181daaf59 DO - 10.1111/IGC.0b013e3181daaf59 ID - Vergote2010 ER - TY - JOUR AU - Colombo, N. AU - Kutarska, E. AU - Dimopoulos, M. AU - Bae, D. S. AU - Rzepka-Gorska, I. AU - Bidzinski, M. PY - 2012 DA - 2012// TI - Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.8082 DO - 10.1200/JCO.2011.38.8082 ID - Colombo2012 ER - TY - JOUR AU - Banerjee, S. AU - Oza, A. M. AU - Birrer, M. J. AU - Hamilton, E. P. AU - Hasan, J. AU - Leary, A. PY - 2018 DA - 2018// TI - Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdy023 DO - 10.1093/annonc/mdy023 ID - Banerjee2018 ER - TY - JOUR AU - Kaye, S. B. AU - Lubinski, J. AU - Matulonis, U. AU - Ang, J. E. AU - Gourley, C. AU - Karlan, B. Y. PY - 2012 DA - 2012// TI - Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.9215 DO - 10.1200/JCO.2011.36.9215 ID - Kaye2012 ER - TY - JOUR AU - Wilson, M. K. AU - Pujade-Lauraine, E. AU - Aoki, D. AU - Mirza, M. R. AU - Lorusso, D. AU - Oza, A. M. PY - 2017 DA - 2017// TI - Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdw663 DO - 10.1093/annonc/mdw663 ID - Wilson2017 ER - TY - JOUR AU - Rolim, L. C. AU - Silva, E. M. K. AU - Flumignan, R. L. G. AU - Abreu, M. AU - Dib, S. A. PY - 2019 DA - 2019// TI - Cochrane systematic review of acetyl-L-Carnitine for the treatment of diabetic polyneuropathy JO - Eur J Vasc Endovasc Surg VL - 58 UR - https://doi.org/10.1016/j.ejvs.2019.06.963 DO - 10.1016/j.ejvs.2019.06.963 ID - Rolim2019 ER - TY - JOUR AU - Colombo, N. AU - Sessa, C. AU - Bois, A. AU - Ledermann, J. AU - McCluggage, W. G. AU - McNeish, I. PY - 2019 DA - 2019// TI - ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz062 DO - 10.1093/annonc/mdz062 ID - Colombo2019 ER - TY - JOUR AU - Bergamini, A. AU - Pisano, C. AU - Napoli, M. AU - Arenare, L. AU - Della Pepa, C. AU - Tambaro, R. PY - 2017 DA - 2017// TI - Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin JO - Gynecol Oncol VL - 144 UR - https://doi.org/10.1016/j.ygyno.2016.10.023 DO - 10.1016/j.ygyno.2016.10.023 ID - Bergamini2017 ER - TY - JOUR AU - Crespo, G. AU - Sierra, M. AU - Losa, R. AU - Berros, J. P. AU - Villanueva, N. AU - Fra, J. PY - 2011 DA - 2011// TI - Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study JO - Int J Gynecol Cancer VL - 21 UR - https://doi.org/10.1097/IGC.0b013e31820d738c DO - 10.1097/IGC.0b013e31820d738c ID - Crespo2011 ER - TY - STD TI - McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R Jr. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. BMC Cancer. 2018;18:1292. ID - ref27 ER - TY - JOUR AU - Gabizon, A. A. AU - Patil, Y. AU - La-Beck, N. M. PY - 2016 DA - 2016// TI - New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy JO - Drug Resist Updat VL - 29 UR - https://doi.org/10.1016/j.drup.2016.10.003 DO - 10.1016/j.drup.2016.10.003 ID - Gabizon2016 ER - TY - JOUR AU - Blank, N. AU - Laskov, I. AU - Kessous, R. AU - Kogan, L. AU - Lau, S. AU - Sebag, I. A. PY - 2017 DA - 2017// TI - Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin JO - Cancer Chemother Pharmacol VL - 80 UR - https://doi.org/10.1007/s00280-017-3412-8 DO - 10.1007/s00280-017-3412-8 ID - Blank2017 ER - TY - JOUR AU - Pease, D. F. AU - Peterson, B. A. AU - Gilles, S. AU - Hordinsky, M. K. AU - Bohjanen, K. A. AU - Skubitz, K. M. PY - 2019 DA - 2019// TI - Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity JO - Cancer Chemother Pharmacol VL - 84 UR - https://doi.org/10.1007/s00280-019-03849-8 DO - 10.1007/s00280-019-03849-8 ID - Pease2019 ER -